EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study

Mathilde Osty, Romain Altwegg iD, Mélanie Serrero, Alban Benezech, Albane Lecomte, Guillaume Cadiot, Lucine Vuitton, Anne Wampach, Stéphane Nancey, Anthony Buisson, Catherine le Berre, Clea Rouillon und 20 weitere

Alimentary Pharmacology & Therapeutics · 2025-08 · 62 (4) · 430-439

DOI: 10.1111/apt.70199 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.05.2025. Verfasst von Mathilde Osty und 31 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hôpital Henri Mondor, APHP, Créteil, France. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Janus Kinase Inhibitors, Piperidines, Pyrimidines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching.

Aim

To evaluate the effectiveness and safety of a second JAK inhibitor in UC.

Methods

This was a multicentre, retrospective, observational cohort including patients with moderate to severe UC who received a second‐line of JAKi after failure or intolerance of a first. The primary outcome was steroid‐free clinical remission (SFCR) at Weeks 8–14, defined as a partial Mayo score of 2 or less with no individual sub‐score above 1.

Results

Among the 169 patients from 28 participating centres, 105 received upadacitinib, 54 filgotinib and 10 tofacitinib as a second‐line of JAKi. Overall, 81/169 achieved SFCR at Weeks 8–14: 58/105 with upadacitinib, 18/54 with filgotinib and 5/10 with tofacitinib ( p = 0.03). In the multivariate analysis, upadacitinib was independently associated with higher odds of SFCR than filgotinib (OR = 3.15, 95% CI [1.52–6.79]). With a median follow‐up duration of 96 days, drug persistence at 6 months was 72.8% with upadacitinib, 57.2% with filgotinib and 66.7% with tofacitinib ( p = 0.099). 24.3% of patients (41/169) experienced at least one adverse event leading to treatment withdrawal in 9 patients (5%). No cases of death, cancer, or major acute cardiovascular events were reported.

Conclusion

A second‐line of JAKi provided clinical remission in about half of patients after induction, and was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeJanus Kinase InhibitorsPiperidinesPyrimidinesHeterocyclic Compounds, 3-RingPyrrolesPyrrolidinesHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedYoung AdultPyridinesTriazoles

Stichwörter der Autor:innen

biologics (IBD)disease‐basedtopicsulcerative colitis

Substanzen

Janus Kinase InhibitorsPiperidinestofacitinibPyrimidinesupadacitinibHeterocyclic Compounds, 3-RingPyrrolesPyrrolidinesGLPG0634Pyridines

Autor:innen und Institutionen

  • Gastroenterology Department, Hôpital Henri Mondor, APHP, Créteil, France.
  • Gastroenterology Department, Hôpital ST Eloi, Montpellier, France.
  • Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), University of Aix-Marseille, Marseille, France.
  • Gastroenterology Department, Hôpital Henri Duffaut, Avignon, France.
  • Gastroenterology Department, CH Valenciennes, Valenciennes, France.
  • Gastroenterology Department, CHU de Reims, Faculté de Médecine de Reims, Reims, France.

ORCID-Profile: Romain Altwegg, David Laharie

Zitieren

APA

Osty, M., Altwegg, R., Serrero, M., Benezech, A., Lecomte, A., Cadiot, G., Vuitton, L., Wampach, A., Nancey, S., Buisson, A., le Berre, C., Rouillon, C., Gilletta, C., Goutorbe, F., Fumery, M., Hammoudi, N., Caillo, L., Vidon, M., Arab, N., …, & GETAID‐J2J group (2025). Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. Alimentary Pharmacology & Therapeutics, 62(4), 430-439. https://doi.org/10.1111/apt.70199

Vancouver

Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, et al. Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. Alimentary Pharmacology & Therapeutics. 2025;62(4):430-439. doi:10.1111/apt.70199

BibTeX
@article{Osty2025,
  author = {Osty, Mathilde and Altwegg, Romain and Serrero, Mélanie and Benezech, Alban and Lecomte, Albane and Cadiot, Guillaume and Vuitton, Lucine and Wampach, Anne and Nancey, Stéphane and Buisson, Anthony and le Berre, Catherine and Rouillon, Clea and Gilletta, Cyrielle and Goutorbe, Felix and Fumery, Mathurin and Hammoudi, Nassim and Caillo, Ludovic and Vidon, Mathias and Arab, Nadia and Sickersen, Gaelle and Cavicchi, Maryan and Vieujean, Sophie and Charkaoui, Maeva and Richard, Nicolas and Wils, Pauline and Caron, Bénédicte and Amiot, Aurélien and Nuzzo, Alexandre and Laharie, David and Kirchgesner, Julien and Uzzan, Mathieu and GETAID‐J2J group, GETAID‐J2J group},
  title = {Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {62},
  number = {4},
  pages = {430--439},
  doi = {10.1111/apt.70199}
}
Kostenlos starten →